Olema stock surges on Novartis deal and $250M private placement

On Monday, Olema Pharmaceuticals experienced a surge of over 10% in its share price following the announcement of a new clinical trial collaboration with Novartis (SIX:NOVN) and a substantial private placement. The agreements are set to advance the company's development of targeted therapies for breast cancer.